Advanced imaging of cardiac sarcoidosis

Journal of Nuclear Medicine

Volumn 55, Issue 1, 2014, Pages 99-106

  Schatka, Imke ^a   Bengel, Frank M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cardiac sarcoidosis; Inflammation; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GALLIUM 67; RUBIDIUM 82; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADVERSE OUTCOME; ARTICLE; ASYMPTOMATIC DISEASE; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR MAGNETIC RESONANCE; CARDITIS; CLINICAL EVALUATION; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY INTERVENTION; GOLD STANDARD; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART SCINTISCANNING; HEART VENTRICLE TACHYCARDIA; HISTOPATHOLOGY; HUMAN; IMAGE GUIDED BIOPSY; INTERMETHOD COMPARISON; MORBIDITY; MORTALITY; MYOCARDIAL PERFUSION IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; [18F]-DEOXYGLUCOSE; CARDIOMYOPATHY; CLINICAL TRIAL (TOPIC); HEART DISEASE; INFLAMMATION; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REPRODUCIBILITY; REVIEW; SCINTISCANNING;

[18F]-DEOXYGLUCOSE; CARDIAC SARCOIDOSIS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

CARDIOMYOPATHIES; CLINICAL TRIALS AS TOPIC; FLUORODEOXYGLUCOSE F18; HEART DISEASES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SARCOIDOSIS;

EID: 84894820883     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.115121     Document Type: Article

References (80)

1. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160: 736-755.
2. Rybicki BA, Iannuzzi MC. Epidemiology of sarcoidosis: recent advances and future prospects. Semin Respir Crit Care Med. 2007;28: 22-35.
3. Newman LS, Rose CS, Bresnitz EA, et al. A case control etiologic study of sarcoidosis environmental and occupational risk factors. Am J Respir Crit Care Med. 2004;170: 1324-1330.
4. du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J Intern Med. 2003;253: 4-17.
5. Rybicki BA, Iannuzzi MC, Frederick MM, et al. Familial aggregation of sarcoidosis: a case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med. 2001;164: 2085-2091.
6. Doughan AR, Williams BR. Cardiac sarcoidosis. Heart. 2006;92: 282-288.
7. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978;58: 1204-1211.
8. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol. 1999;52: 1173-1186.
9. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976;278: 455-469.
10. Sharma OP, Maheshwari A, Thaker K. Myocardial sarcoidosis. Chest. 1993;103: 253-258.
11. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest. 2008;133: 1426-1435.
12. Gideon NM, Mannino DM. Sarcoidosis mortality in the United States, 1979-1991: an analysis of multiple-cause mortality data. Am J Med. 1996;100: 423-427.
13. Tachibana T, Iwai K, Takemura T. Study on cause of death in the patients with sarcoidosis in Japan. Vasc Diffuse Lung Dis. 1992;9: 307.
14. Tavora F, Cresswell N, Li L, Ripple M, Solomon C, Burke A. Comparison of necropsy findings in patients with sarcoidosis dying suddenly from cardiac sarcoidosis versus dying suddenly from other causes. Am J Cardiol. 2009;104: 571-577.
15. Roberts WC, McAllister HA, Ferrans VJ. Sarcoidosis of the heart: a clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med. 1977;63: 86-108.
16. Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm. 2007;4: 1292-1299.
17. Kandolin R, Lehtonen J, Kupari M. Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-Aged adults. Circ Arrhythm Electrophysiol. 2011;4: 303-309.
18. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart. 2011;97: 2078-2087.
19. Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27: 217-222.
20. Sekiguchi M, Numao Y, Imai M, Furuie T, Mikami R. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis: concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J. 1980;44: 249-263.
21. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-Term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88: 1006-1010.
22. Sekhri V, Sanal S, Delorenzo LJ, Aronow WS, Maguire GP. Cardiac sarcoidosis: a comprehensive review. Arch Med Sci. 2011;7: 546-554.
23. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol. 2009;20: 578-583.
24. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest. 2012;141: 154-162.
25. Okura Y, Dec GW, Hare JM, et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol. 2003;41: 322-329.
26. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J. 2009; 157: 9-21.
27. Schuller JL, Lowery CM, Zipse M, et al. Diagnostic utility of signal-Averaged electrocardiography for detection of cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16: 70-76.
28. Freeman AM, Curran-Everett D, Weinberger HD, et al. Predictors of cardiac sarcoidosis using commonly available cardiac studies. Am J Cardiol. 2013;112: 280-285.
29. Uemura A, Morimoto S, Kato Y, et al. Relationship between basal thinning of the interventricular septum and atrioventricular block in patients with cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2005;22: 63-65.
30. Smedema JP. Tissue Doppler imaging in cardiac sarcoidosis. Eur J Echocardiogr. 2008;9: 579-580.
31. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore). 2004;83: 315-334.
32. Cooper LT, Baughman KL, Feldman AM, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116: 2216-2233.
33. Kandolin R, Lehtonen J, Graner M, et al. Diagnosing isolated cardiac sarcoidosis. J Intern Med. 2011;270: 461-468.
34. Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol. 2013;29: 1015.e1-3.
35. Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR. 2005;185: 110-115.
36. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6: 501-511.
37. Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK. A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics. 2009;29: 89-103.
38. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120: 1969-1977.
39. Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJR. 2008;191: 862-869.
40. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45: 1683-1690.
41. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest. 2002;122: 1895-1901.
42. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med. 2001;110: 520-527.
43. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med. 2007;48: 35-45.
44. Abel ED. Glucose transport in the heart. Front Biosci. 2004;9: 201-215.
45. Iozzo P, Chareonthaitawee P, Di Terlizzi M, Betteridge DJ, Ferrannini E, Camici PG. Regional myocardial blood flow and glucose utilization during fasting and physiological hyperinsulinemia in humans. Am J Physiol Endocrinol Metab. 2002;282: E1163-E1171.
46. 18FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease. J Thorac Imaging. 2012;27: 263-268.
47. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study. Clin Nucl Med. 2013;38: e171-e177.
48. Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18: 926-936.
49. 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR. 2008;190: W151-W156.
50. 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J. 2005;26: 1538-1543.
51. Morooka M, Moroi M, Ito K, Minamimoto R. Heparin vs. long fasting method: which inhibits the FDG myocardial physiological uptake more strongly? [abstract]. J Nucl Med. 2013;54(suppl): 406P.
52. McArdle BA, Leung E, Ohira H, et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20: 297-306.
53. 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53: 241-248.
54. 18F-FDG uptake. J Nucl Med. 2007;48: 234-239.
55. 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med. 2004;45: 1989-1998.
56. 18F-FDG PET. J Nucl Med. 2003;44: 1030-1036.
57. Nelson JE, Kirschner PA, Teirstein AS. Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis. 1996;13: 178-182.
58. 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging. 2008;35: 933-941.
59. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and lowcarbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol. 2013;20: 120-127.
60. Campbell P, Stewart GC, Padera RF, et al. Evaluation for cardiac sarcoidosis: uncertainty despite contemporary multi-modality imaging [abstract]. J Card Fail. 2010;16(suppl): S107.
61. 18F-FDG use in inflammation and infection. J Nucl Med. 2013;54: 647-658.
62. 18F-fluorodoexyglucose positron emission tomography? Circ Cardiovasc Imaging. 2013;6: 617-626.
63. Blankstein R, Naya M, Osborne M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoid. J Am Coll Cardiol. October 1, 2013 [Epub ahead of print].
64. DiFilippo FP, Brunken RC. Do implanted pacemaker leads and ICD leads cause metal-related artifact in cardiac PET/CT? J Nucl Med. 2005;46: 436-443.
65. Ghafarian P, Aghamiri SM, Ay MR, et al. Is metal artefact reduction mandatory in cardiac PET/CT imaging in the presence of pacemaker and implantable cardioverter defibrillator leads? Eur J Nucl Med Mol Imaging. 2011;38: 252-262.
66. Schneider S, Batrice A, Rischpler C, Eiber M, Ibrahim T, Nekolla SG. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur Heart J. 2013 Aug 23, 2013 [Epub ahead of print].
67. Le Guludec D, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis: clinical value of technetium-99m sestamibi tomoscintigraphy. Chest. 1994;106: 1675-1682.
68. Okayama K, Kurata C, Tawarahara K, Wakabayashi Y, Chida K, Sato A. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest. 1995;107: 330-334.
69. Hirose Y, Ishida Y, Hayashida K, et al. Myocardial involvement in patients with sarcoidosis: an analysis of 75 patients. Clin Nucl Med. 1994;19: 522-526.
70. Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology. 2000;94: 193-199.
71. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis. 2010;52: 336-346.
72. Milburn HJ, Poulter LW, Dilmec A, Cochrane GM, Kemeny DM. Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol. 1997;108: 105-113.
73. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-Term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005;95: 143-146.
74. Sadek MM, Yung D, Birnie DH, Beanlands RS, Nery PB. Corticosteroid therapy for cardiac sarcoidosis: a systematic review. Can J Cardiol. 2013;29: 1034-1041.
75. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013;61: e6-e75.
76. Bussinguer M, Danielian A, Sharma OP. Cardiac sarcoidosis: diagnosis and management. Curr Treat Options Cardiovasc Med. 2012;14: 652-664.
77. Akashi H, Kato TS, Takayama H, et al. Outcome of patients with cardiac sarcoidosis undergoing cardiac transplantation: single-center retrospective analysis. J Cardiol. 2012;60: 407-410.
78. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant. 2007;26: 714-717.
79. Terasaki F, Tsuji M, Kizawa S, et al. Sarcoidosis does not belong to or overlap with immunoglobulin G4-related diseases based on an assessment of serum immunoglobulin G4 levels in cardiac and noncardiac sarcoidosis. Hum Pathol. 2012;43: 818-825.
80. Kadosh B, Steele J, Gulkarov I, Mamkin I. Cardiac sarcoidosis. J Am Coll Cardiol. 2013;61: 1548.